

39/869122

JCO3 Rec'd PCT/PTC 25 JUN 2001

PATENT APPLICATION

#4/A
M.J.
9/24/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Shohei TANAKA, et al.

U.S. National Stage of PCT/JP99/07236

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: June 25, 2001

For: PHARMACEUTICAL COMPOSITIONS FOR TREATING BONE LESIONS IN
MULTIPLE MYELOMA

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Pages 2-3, please replace the first full paragraph with the following:

In treating multiple myeloma, use is mainly made of chemotherapies (MP therapy, VAD therapy, C-VAD therapy, polypharmacy, etc.) and chemotherapy with the use of IFN- α . Also, topical radiotherapy and the like are selected depending on the bone lesion conditions (Clinical Oncology, edited by Japan Clinical Oncology Group, published in 1996 by Gan to Kagakuryoho Sha). As the results of the long-term observation on patients with multiple myeloma under chemotherapy, it is reported that a bone resorption marker in urine did not correlate to changes in M proteins due to chemotherapy in many cases, though a tendency toward a decrease in the bone resorption marker was observed in a chemotherapy reaction group

RECEIVED
JUN 28 2001
COMM. FOR PAT.
WASHINGTON, D.C.
20540